Compare Organon & Co. Common Stock (OGN) vs Rubrik Inc. Class A Common Stock (RBRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Rubrik Inc. Class A Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Rubrik Inc. Class A Common Stock trades at $111.47 (market cap $24.56B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 6.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Rubrik Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Rubrik Inc. Class A Common Stock for 4 Days on average.
| OGN | RBRK | |
|---|---|---|
Market Cap | $3.62B | $24.56B |
Volume | 2,892,999 | 2,289,465 |
Sector | Health | Technology |
52-Week High | $13.81 | $125.80 |
52-Week Low | $5.70 | $43.81 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $11.04B | $23.96B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Rubrik (RBRK) trades at $118.47, down 1.28% on the day, with strong technical momentum showing bullish moving averages and support at $118. The company demonstrates impressive revenue growth, with 2026 revenue reaching $1.5B and recent earnings beats, though profitability remains negative with a -16.5% net margin. Recent news highlights expansion of AI security offerings including Rubrik Code Guardian and strong institutional buying interest.
Rubrik presents a compelling growth story in cybersecurity with 100% analyst buy ratings and $105.08 consensus target, though current price exceeds this. Key risks include persistent losses despite revenue growth and competitive AI security landscape. The stock's technical strength and AI-driven demand create upside potential, but profitability concerns warrant careful monitoring of margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Rubrik Inc. Class A Common Stock
Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →
